Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
The European Commission has approved CinnaGen’s Zandoriah — teriparatide biosimilar — for the treatment of osteoporosis in adults, marking a significant regulatory milestone for the peptide biosimilar market. Teriparatide — recombinant human parathyroid hormone (PTH 1–34), a 34-amino acid peptide — has been a mainstay anabolic osteoporosis therapy since Eli Lilly’s Forteo gained approval in 2002. The EC decision signals that peptide biosimilars are entering a new phase of regulatory maturity, with potentially far-reaching implications for manufacturing capacity, pricing dynamics, and CDMO strategy across the broader peptide therapeutics field.
Context
Teriparatide is a truncated form of parathyroid hormone — specifically the biologically active N-terminal 1–34 amino acid fragment of the 84-amino acid native hormone. Unlike antiresorptive agents — bisphosphonates, denosumab — that slow bone loss, teriparatide is anabolic: it stimulates new bone formation when administered intermittently. This mechanism makes it uniquely valuable for patients with severe osteoporosis who have already suffered fractures or failed other therapies.
Eli Lilly’s Forteo dominated the market for nearly two decades, generating peak annual sales of approximately 1.4 billion dollars before losing US patent exclusivity in 2019. Since then, the terrain has shifted: the US FDA approved its first teriparatide biosimilar (from Alvogen/Teva) in 2023, and the EMA has now followed with CinnaGen’s Zandoriah receiving EC approval in June 2026. CinnaGen, an Iran-based biopharmaceutical company with a growing European regulatory footprint, positions this approval as a step toward expanding biosimilar access across the EU market.
The Data
Active Ingredient | Teriparatide, also known as PTH 1–34 | Teriparatide, also known as PTH 1–34.
Sequence Length | 34 amino acids | 34 amino acids.
Molecular Weight | ~4,118 Da | ~4,118 Da.
Expression System | E. coli (recombinant) | E. coli (recombinant).
Route | Subcutaneous injection | Subcutaneous injection.
Approval Year, also known as EU | 2003 | 2026.
Manufacturer | Eli Lilly | CinnaGen.
Global Market (2026) | ~1.8 billion dollars (including all teriparatide products).
Expert Insight
Anti-Pattern: Assuming peptide biosimilars follow the small-molecule generic playbook. The single most common mistake industry analysts make is treating peptide biosimilars as interchangeable with chemically synthesized generics. Teriparatide is a recombinant peptide produced in E. coli, not a chemically synthesized small molecule. Biosimilarity for peptides requires demonstrating comparability across primary sequence, higher-order structure, post-translational modifications, and biological activity — a burden that sits between small-molecule generics and monoclonal antibody biosimilars in complexity.
Experienced peptide developers know that E. coli expression of the 34-amino acid PTH fragment is deceptively challenging. The peptide is prone to methionine oxidation (Met8, Met18), deamidation (Asn10, Asn16), and aggregation at formulation concentrations. A teriparatide biosimilar manufacturer must replicate not just the amino acid sequence but also the impurity profile, aggregation kinetics, and delivery device performance of the originator. The EC’s approval of Zandoriah confirms that CinnaGen has navigated these hurdles —. it also serves as a reminder that the analytical and CMC burden for peptide biosimilars is substantial. often underestimated by teams coming from a small-molecule background.
What Experienced Teams Know: The real manufacturing bottleneck for teriparatide biosimilars is not the fermentation step but downstream purification. The 34-mer peptide requires multiple chromatography steps (typically ion-exchange followed by reversed-phase HPLC) to achieve pharmaceutical-grade purity, and HPLC capacity remains the rate-limiting factor across the broader peptide CDMO landscape. With semaglutide and tirzepatide consuming vast amounts of preparative HPLC capacity worldwide, teriparatide biosimilar manufacturers face direct competition for purification slots — a dynamic that influences both cost of goods and time-to-market for every new peptide biosimilar entrant.
Further Reading
- The Race to Biosimilar Semaglutide: Who’s Ahead and What It Means for Price
- FDA and EMA Peptide Drug Approvals: A 2020–2026 Regulatory Analysis
- The Economics of Peptide API Manufacturing: A Cost Breakdown
[Natural sign-off — one sentence summary of why this matters.]
Last reviewed: June 2026. Peptide Proof Editorial Team. Source: FiercePharma — European Commission Approves CinnaGen’s Zandoriah — Teriparatide Biosimilar —; Eli Lilly SEC filings; EMA public assessment reports.
